Introduction
Sleep Disordered breathing (SDB) is a modern world epidemic with an estimated prevalence of 26% 1 . It is implicated as a risk factor in the development of numerous cardiovascular conditions including congestive heart failure, hypertension, atrial fibrillation and stroke 2 . Furthermore, several large observational trials have identified SDB as a risk factor for premature mortality [3] [4] [5] . Despite extensive evidence of its detrimental impact on health, SDB remains under-diagnosed and under-treated 6 .
Moreover, delayed diagnosis of SDB may be adding to the burden of complications from other medical conditions such as diabetes 7 and renal failure 8 . Thus, efforts to more quickly diagnose and treat persons with SDB have the potential to reduce negative outcomes 9 .
Recent efforts to perform SDB screening and treatment in hospitalized patients have been encouraging. Studies by ourselves and others have shown that early diagnosis of SDB and intervention in hospitalized patients resulted in a reduction in 30-day and 6 month readmissions in patients admitted for acute heart failure and chronic obstructive pulmonary disease (COPD) exacerbation [10] [11] [12] . In this analysis we extend our previous findings to include a substantially larger number of patients to not only confirm the high prevalence of unrecognized SDB in hospitalized patients, but also to determine its impact on survival of patients after early intervention with positive airway pressure (PAP)
therapy.
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Methodology
Between March 2013 to July 2016, 5062 patients admitted to the cardiology, internal medicine, and family practice services with a body mass index (BMI, weight
[kg]/height, [m 2 ]) ≥ 30 were screened for SDB with the STOP (snoring, tiredness during daytime, observed apnea, high blood pressure). In addition, patients admitted to the advanced heart failure service with the diagnosis of CHF were screened using the full STOP-BANG questionnaire 13 . The questionnaires were administered by a respiratory therapist. The STOP and STOP-BANG questionnaires are easy to use succinct tools which can be administered by health care professionals with a minimal increase in work burden. The STOP-BANG was administered to cardiology service patients since there is evidence that patients with heart failure do not always exhibit excessive daytime sleepiness/tiredness 14 . The STOP-BANG adds objective measures of BMI, neck collar size (> 40 cm), gender (males are at higher risk) and age ( >50 years). The admitting team was notified if the STOP/ STOP-BANG questionnaire was positive (answering yes to two or more items in STOP and 3 or more in STOP-BANG) who then contacted a boardcertified pulmonary sleep medicine physician (inpatient consult service) to determine whether a follow-up consultation was necessary ( Figure 1) . A consultation by a boardcertified sleep specialist determined if the patient required a nocturnal high resolution plethysmography (HRPO). The contra-indications for in-hospital HRPO included oxygen Using AHI ≥ 5 events per hour as the diagnostic criteria for SDB, we constructed a receiver-operator curve to describe the accuracy of correctly identifying SDB with the ODI. The area under the curve (AUC) was calculated. Additionally, a relative BlandAltman plot was constructed which compared the ratio of ODI to AHI. As discussed in
Bland-Altman (1986), the relative Bland-Altman plot (using log-transformed data) is preferable when the data show fanning, or higher variability with increased mean values.
Finally, the Kaplan-Meier survival curves for SDB patients' adherent to therapy and SDB patients non-adherent to therapy were constructed and compared with a Logrank test. To adjust for potential confounding variables because this is an observational study, a propensity score analysis was conducted. Specifically, propensity scores for each patient were calculated with a logistic regression model that predicted compliance using age, BMI, race, heart failure, asthma/COPD, and diuretic use. Other demographic variables such as AHI, other medication use, and other comorbidities were considered but not included in the model due to their low association with compliance. Finally, an inverse propensity score weighted Log-Rank survival analysis was conducted.
Results
Data from a total of 5062 patients screened from March 2013 to July 2016 were analyzed. Overall, the mean age was 60. As shown in Figure confirmation rate of 87% can be applied to the entire cohort of those patients who had an ODI > 5, the estimated prevalence of SDB in the entire cohort of 5062 patients is 18.7%.
As shown in Table 2 , multivariate logistic regression analysis revealed that age between 51 and 61, male sex, higher BMI greater than 38 kg/m 2 , and the presence of CHF, CRF, HTN, Asthma/COPD were independently associated with SDB (all pvalues<0.005). However, race, atrial fibrillation and type 2 diabetes were not significantly associated with SDB. The likelihood ratio (LR) of SDB with ODI of > 15 was 6.47 and ODI of > 20 was 9.19 ( Table 4 ). The demographic characteristics of patients who had HRPO while in the hospital but did not follow-up at our sleep center for a PSG were compared with patients who had HRPO and subsequent PSG. Those who had both procedures were more likely to be Black and had a statistically higher
Recognition and treatment of sleep disordered breathing in obese hospitalized patients may improve survival. The HoSMed database percentage of many, but not all comorbid medical conditions. However, the differences were relatively small. (Table 5 ).
As shown in Figure 2 , there was a strong correlation between inpatient ODI and outpatient AHI with an AUC of 0.83 on the receiver operator curve using AHI > 5 for confirmation of SDB. The relative Bland-Altman plot ( Figure 3 , Table 3 ) revealed that there was no significant bias when using ODI versus AHI to define SDB.
Survival curves for the 149 patients with SDB and adherent with PAP therapy and the 309 patients with SDB who were non-adherent were compared ( Figure 4 ). The mean and median follow-up durations were 609 and 570 days respectively. In contrast to non-adherent patients, those who were adherent to PAP therapy were found to have significantly better survival (Log-rank test p=0.016). In an inverse probability weighted survival analysis (using propensity score), these differences were confirmed and were even more statistically significant (p-value=0.001).
Discussion
In this analysis of a large database of hospitalized patients, we confirmed that there is a high prevalence of undiagnosed SDB. Furthermore, follow-up of these patients for a mean of 609 days demonstrated that those who were adherent to PAP had a survival advantage in comparison to those who were non-compliant. These findings add to the Recognition and treatment of sleep disordered breathing in obese hospitalized patients may improve survival. The HoSMed database larger body of evidence that diagnosis and treatment of SDB with PAP can reduce longterm mortality.
In our single center database of more than 5000 patients, the estimated prevalence of undiagnosed SDB was 18.7%. The true prevalence rate may be even higher if there are patients who screened falsely negative. In contrast, recent estimates of the prevalence of SDB in the community are much higher 1, 19, 20 with 83.8% of men found to have an AHI > 5 in one study 21 . It is likely that differences between our results and these general population estimates are related to dissimilarities in population characteristics, methods of ascertainment and definitions of SDB. Irrespective of the true prevalence rate in hospitalized patients, it appears that there are large numbers of unrecognized SDB patients in this population.
Prior data suggests that SDB in hospitalized patients is associated with greater morbidity and mortality. This suggests that SDB treatment is an area that may have potential for improving outcomes. A large multi-center study of SDB in hospitalized type 2 diabetes patients showed that over 60% of the patients had an AHI >5 and a quarter of the patients had moderate to severe OSA 22 . Shear et al screened hospitalized elderly patients and identified 40% as high-risk for OSA. These high-risk patients were also found to have reduced sleep (as measured by actigraphy) and poor self-reported sleep quality during their hospital stay 23 . A recent study found OSA to be a risk factor for postoperative respiratory failure requiring ICU transfer in patients undergoing orthopedic surgery 24 . In a large prospective study of patients hospitalized for acute heart failure, Recognition and treatment of sleep disordered breathing in obese hospitalized patients may improve survival. The HoSMed database diagnosis of SDB was independently associated with post-discharge mortality 25 .
Lindenauer et al showed that among patients hospitalized with pneumonia presence of OSA increases risk for intubation, ICU transfers and higher cost of care 26 .
A few recent studies have shown that early intervention with PAP therapy in patients detected to have SDB in hospitalized settings may improve clinical outcomes.
Kauta et al showed that early detection and treatment of OSA in patients admitted to cardiac care unit (CCU) reduced 30-day readmission 10 . Likewise, we studied patients admitted with acute heart failure who were diagnosed with SDB in the hospital. Early intervention with PAP therapy resulted in a significant reduction in 6-month readmission in those compliant with therapy 11 . A similar reduction in readmission after early PAP intervention was also shown by our group in patients admitted with a COPD exacerbation and diagnosed with SDB. Early recognition of high-risk patients for OSA in hospitalized patients also predicted more frequent rapid response events which were reduced in patients who were successfully intervened with PAP therapy 27 .
The major finding in this study was that patients treated and compliant on PAP therapy showed a significant survival advantage compared to those who were noncompliant. We do not believe that differences in various comorbidities explains the observed survival advantage of PAP adherent patients in that there were few differences in the prevalence of important comorbid conditions between the two groups and this observation was supported using an inverse propensity score analysis which accounted for differences between the two groups. This finding also is consistent with our recent
Recognition and treatment of sleep disordered breathing in obese hospitalized patients may improve survival. The HoSMed database data targeting CHF patients. In that latter analysis, we observed a trend towards improved survival in patients compliant with PAP therapy; however, it did not reach statistical significance due to the small numbers of patients. In this large sample size comprising patients with various co-morbid conditions, we extend our previous findings by demonstrating a significant survival benefit in patients with SDB who were compliant with PAP therapy compared to non-compliant patients. In addition, our current analysis includes not only CHF patients, but patients with other medical conditions. Thus, our findings have greater generalizability to a broader spectrum of hospital populations. Our data suggest that once SDB is identified in hospitalized patients, concerted efforts need to be made to initiate and maintain effective PAP therapy.
This study also supports our prior contention that HRPO derived ODI in hospital but failed to get a subsequent PSG at our center were less likely to have several serious comorbid medical conditions. However, the differences between those who did not have a confirmatory PSG and those who did not were small and unlikely to be clinically significant.
Although our study has several important findings, it should be interpreted with the following limitations. First, it is a retrospective observational study. Patients were not
Recognition and treatment of sleep disordered breathing in obese hospitalized patients may improve survival. The HoSMed database prospectively randomized to PAP therapy or sham PAP therapy. It is possible that despite similarities in comorbid conditions between the two groups, factors other than PAP adherence explained the differences in survival that were observed. However, we applied propensity score analysis to account for systematic differences in baseline characteristics between treated and untreated subjects when estimating the effect of treatment on outcomes and the model continued to show a significant statistical difference. Second, the screening was limited to weekdays. However, we do not believe that the patient demographics were different during weekend admissions. Third, due to logistical limitations the screening was limited to medical services only and does not apply to other services. Third, except for CHF patients, patients were screened only if their BMI was > 30 kg/m 2 . Thus, our findings cannot be extrapolated to non-obese patients. Fourth, only 680 (21%) of all screen positive patients underwent a PSG study post discharge at our facility. However, the high correlation of ODI on the HRPO with the PSG AHI suggests that in this population, the ODI is a reasonable surrogate to identify SDB. Finally, patients who screened negative did not undergo either HRPO or PSG. Thus, some patients may have been incorrectly designated as not having SDB.
Despite the afore-mentioned limitations, our study has several strengths. To our knowledge, this is the largest database of SDB in hospitalized patients to date. As such, it provides insight into the extent of undiagnosed and untreated SDB in hospitalized patients and their outcomes. It also demonstrates the utility of using existing clinical
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